Selenium Supplementation in Moderate-Severely Active Ulcerative Colitis Patients Treated With Advanced Therapies

Summary

Micronutrient deficiencies are common in ulcerative colitis (UC). Selenium deficiency is associated with worse disease outcomes including disease flares and need for surgery. Previous in vitro and in vivo studies demonstrated that selenium regulates colonic inflammation, and that selenium supplementation protects against DSS-induced colitis. In this proof-of-concept clinical trial, we aim to test the hypothesis that selenium supplementation in moderate to severely active UC patients will improve responsiveness to advanced therapy such as biologics and small molecules.

Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov

Conditions studied

• Ulcerative Colitis (UC)

Eligibility basics and study details

Study type

Interventional

Phase

Phase 2

Ages

18 to 85 years

Sex

All

Healthy volunteers

Not accepted

Sponsor

Northwestern University

Last updated on ClinicalTrials.gov

May 22, 2026

These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.

US recruiting sites